Solid organ transplant (SOT) recipients appear to have higher rates of mortality from COVID-19 when compared to other populations, attributed to underlying immunosuppression and concomitant co-morbidities.1 Such findings are consistent with other respiratory viral infections that are associated with an increased risk of morbidity and mortality in immunocompromised hosts.2 Further, these patients experience prolonged SARS-CoV-2 shedding which has been linked to emergence of viral mutants. Prolonged shedding also poses a risk of transmission and requires prolonged isolation, potentially leading to delays in medical care.